Program
ertugliflozin
Also written as “Ertugliflozin 5 mg”, “Ertugliflozin” and “Ertugliflozin 15 mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Fatty Liver · Renal Insufficiency, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 200 open or running | phase 3since Oct 7, 2013 | Oct 1, 2009 | none ahead |
| Getz Pharma | 11 open or running | phase 4since Nov 18, 2022 | Nov 18, 2022 | none ahead |
| Humanis Saglık Anonim Sirketi | 10 open or running | phase 1since Dec 3, 2025 | Dec 3, 2025 | none ahead |
Also a collaborator on its studies: Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Oct 1, 2009.
- Apr 27, 2010Phase 1 study in HealthyMerck · NCT01114568 · 12 enrolled
- May 19, 2010Phase 1 study in Diabetes Mellitus, Type 2Merck · NCT01127308 · 6 enrolled
- Oct 13, 2010Phase 1 study in Diabetes Mellitus, Type 2Merck · NCT01223339 · 24 enrolled
- Sep 20, 2013Phase 1 study in Renal InsufficiencyMerck · NCT01948986 · 36 enrolled
- Oct 7, 2013Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT01958671 · 461 enrolled
- Nov 12, 20133 phase 3 studies in Diabetes Mellitus, Type 2Merck · NCT01986881, NCT01986855, NCT01999218
- Jan 9, 20142 phase 3 studies in Diabetes Mellitus, Type 2Merck · NCT02033889, NCT02036515
- Mar 25, 2014Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02099110 · 1,233 enrolled
- Apr 14, 2014Phase 1 study in Diabetes Mellitus, Type 2Merck · NCT02115347 · 16 enrolled
- Aug 25, 2014Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02226003 · 291 enrolled
- Dec 11, 2015Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02630706 · 506 enrolled
- Jul 11, 2019Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT04029480 · 166 enrolled · United States, Belgium, Canada and more
- Nov 18, 2022Getz Pharma's first study: phase 4 study in Fatty LiverNew to Getz PharmaGetz Pharma · NCT05644717 · 164 planned · Pakistan
- Dec 3, 2025Humanis Saglık Anonim Sirketi's first study: phase 1 study in Diabetes Mellitus, Type 2New to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07266779 · 36 enrolled · India
TargetBeta
“Sodium/glucose cotransporter 2 inhibitor; Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC5A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| empagliflozinrule | Boehringer Ingelheim | phase 4 | 142 |
| dapagliflozin | AstraZeneca | phase 4 | 133 |
| Enavogliflozinrule | Daewoong Pharmaceutical | phase 3 | 25 |
| vicadrostat | Boehringer Ingelheim | phase 3 | 16 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07266779Diabetes Mellitus, Type 2 · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Sep 4, 2025 | 36 |
| NCT05644717Fatty Liver · Pakistan | 4 | Recruiting | Getz Pharma | Nov 1, 2025 | 164 |
| NCT04029480Diabetes Mellitus, Type 2 · United States, Belgium, Canada and more | 3 | Completed | Merck | Apr 11, 2025 | 166 |
| NCT02630706Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Dec 27, 2017 | 506 |
| NCT02226003Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Feb 23, 2016 | 291 |
| NCT02115347Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Jan 10, 2015 | 16 |
| NCT02099110Diabetes Mellitus, Type 2 | 3 | Completed | Merck | May 26, 2016 | 1,233 |
| NCT02036515Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jun 6, 2016 | 464 |
| NCT02033889Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Aug 3, 2017 | 621 |
| NCT01999218Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Apr 18, 2017 | 1,326 |
| NCT01986881Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Dec 27, 2019 | 8,246 |
| NCT01986855Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Sep 28, 2016 | 468 |
| NCT01958671Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jul 28, 2016 | 461 |
| NCT01948986Renal Insufficiency | 1 | Completed | Merck | Oct 6, 2014 | 36 |
| NCT01223339Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Feb 2011 | 24 |
| NCT01127308Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Jul 2010 | 6 |
| NCT01114568Healthy | 1 | Completed | Merck | Jun 2010 | 12 |
| NCT01096667Diabetes Mellitus, Type 2 | 2 | Completed | Merck | Feb 9, 2011 | 194 |
| NCT01059825Diabetes Mellitus, Type 2 | 2 | Completed | Merck | Jan 20, 2011 | 375 |
| NCT01054300Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Apr 7, 2010 | 52 |
| NCT01018823Healthy Volunteer | 1 | Completed | Merck | Mar 18, 2010 | 40 |
| NCT00989079Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Dec 11, 2009 | 24 |
How it is read
Names in the registry
- “Ertugliflozin 5 mg”, 10 entries
- “Ertugliflozin”, 8 entries
- “Ertugliflozin 15 mg”, 5 entries
- “Ertugliflozin 10 mg”, 4 entries
- “Ertugliflozin 1 mg”, 2 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 18 studies
- Fatty Liver, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.